172 related articles for article (PubMed ID: 15936883)
1. Antihyperalgesic properties of the cannabinoid CT-3 in chronic neuropathic and inflammatory pain states in the rat.
Dyson A; Peacock M; Chen A; Courade JP; Yaqoob M; Groarke A; Brain C; Loong Y; Fox A
Pain; 2005 Jul; 116(1-2):129-37. PubMed ID: 15936883
[TBL] [Abstract][Full Text] [Related]
2. The role of central and peripheral Cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain.
Fox A; Kesingland A; Gentry C; McNair K; Patel S; Urban L; James I
Pain; 2001 May; 92(1-2):91-100. PubMed ID: 11323130
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy.
Valenzano KJ; Tafesse L; Lee G; Harrison JE; Boulet JM; Gottshall SL; Mark L; Pearson MS; Miller W; Shan S; Rabadi L; Rotshteyn Y; Chaffer SM; Turchin PI; Elsemore DA; Toth M; Koetzner L; Whiteside GT
Neuropharmacology; 2005 Apr; 48(5):658-72. PubMed ID: 15814101
[TBL] [Abstract][Full Text] [Related]
4. Cannabinoids in disguise: Δ9-tetrahydrocannabinol-like effects of tetramethylcyclopropyl ketone indoles.
Wiley JL; Marusich JA; Lefever TW; Grabenauer M; Moore KN; Thomas BF
Neuropharmacology; 2013 Dec; 75():145-54. PubMed ID: 23916483
[TBL] [Abstract][Full Text] [Related]
5. A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain.
Kehl LJ; Hamamoto DT; Wacnik PW; Croft DL; Norsted BD; Wilcox GL; Simone DA
Pain; 2003 May; 103(1-2):175-86. PubMed ID: 12749972
[TBL] [Abstract][Full Text] [Related]
6. The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain.
Bridges D; Ahmad K; Rice AS
Br J Pharmacol; 2001 Jun; 133(4):586-94. PubMed ID: 11399676
[TBL] [Abstract][Full Text] [Related]
7. A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833.
Whiteside GT; Gottshall SL; Boulet JM; Chaffer SM; Harrison JE; Pearson MS; Turchin PI; Mark L; Garrison AE; Valenzano KJ
Eur J Pharmacol; 2005 Dec; 528(1-3):65-72. PubMed ID: 16316650
[TBL] [Abstract][Full Text] [Related]
8. A peripherally restricted cannabinoid receptor agonist produces robust anti-nociceptive effects in rodent models of inflammatory and neuropathic pain.
Yu XH; Cao CQ; Martino G; Puma C; Morinville A; St-Onge S; Lessard É; Perkins MN; Laird JMA
Pain; 2010 Nov; 151(2):337-344. PubMed ID: 20696525
[TBL] [Abstract][Full Text] [Related]
9. Antiemetic and motor-depressive actions of CP55,940: cannabinoid CB1 receptor characterization, distribution, and G-protein activation.
Darmani NA; Sim-Selley LJ; Martin BR; Janoyan JJ; Crim JL; Parekh B; Breivogel CS
Eur J Pharmacol; 2003 Jan; 459(1):83-95. PubMed ID: 12505537
[TBL] [Abstract][Full Text] [Related]
10. Low dose combination of morphine and delta9-tetrahydrocannabinol circumvents antinociceptive tolerance and apparent desensitization of receptors.
Smith PA; Selley DE; Sim-Selley LJ; Welch SP
Eur J Pharmacol; 2007 Oct; 571(2-3):129-37. PubMed ID: 17603035
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo pharmacology of synthetic olivetol- or resorcinol-derived cannabinoid receptor ligands.
Cascio MG; Bisogno T; Palazzo E; Thomas A; van der Stelt M; Brizzi A; de Novellis V; Marabese I; Ross R; van de Doelen T; Brizzi V; Pertwee R; Maione S; Di Marzo V
Br J Pharmacol; 2006 Oct; 149(4):431-40. PubMed ID: 16953186
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain.
Xu JJ; Diaz P; Astruc-Diaz F; Craig S; Munoz E; Naguib M
Anesth Analg; 2010 Jul; 111(1):99-109. PubMed ID: 20522703
[TBL] [Abstract][Full Text] [Related]
13. The CB2 cannabinoid receptor-selective agonist O-3223 reduces pain and inflammation without apparent cannabinoid behavioral effects.
Kinsey SG; Mahadevan A; Zhao B; Sun H; Naidu PS; Razdan RK; Selley DE; Imad Damaj M; Lichtman AH
Neuropharmacology; 2011; 60(2-3):244-51. PubMed ID: 20849866
[TBL] [Abstract][Full Text] [Related]
14. Analgesic effects of cannabinoid receptor agonist WIN55,212-2 in the nucleus cuneiformis in animal models of acute and inflammatory pain in rats.
Ebrahimzadeh M; Haghparast A
Brain Res; 2011 Oct; 1420():19-28. PubMed ID: 21911208
[TBL] [Abstract][Full Text] [Related]
15. Actions of the endocannabinoid transport inhibitor AM404 in neuropathic and inflammatory pain models.
Mitchell VA; Greenwood R; Jayamanne A; Vaughan CW
Clin Exp Pharmacol Physiol; 2007 Nov; 34(11):1186-90. PubMed ID: 17880375
[TBL] [Abstract][Full Text] [Related]
16. The psychoactive plant cannabinoid, Delta9-tetrahydrocannabinol, is antagonized by Delta8- and Delta9-tetrahydrocannabivarin in mice in vivo.
Pertwee RG; Thomas A; Stevenson LA; Ross RA; Varvel SA; Lichtman AH; Martin BR; Razdan RK
Br J Pharmacol; 2007 Mar; 150(5):586-94. PubMed ID: 17245367
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanisms involved in the asymmetric interaction between cannabinoid and opioid systems.
Viganò D; Rubino T; Vaccani A; Bianchessi S; Marmorato P; Castiglioni C; Parolaro D
Psychopharmacology (Berl); 2005 Nov; 182(4):527-36. PubMed ID: 16079992
[TBL] [Abstract][Full Text] [Related]
18. Receptor mechanism and antiemetic activity of structurally-diverse cannabinoids against radiation-induced emesis in the least shrew.
Darmani NA; Janoyan JJ; Crim J; Ramirez J
Eur J Pharmacol; 2007 Jun; 563(1-3):187-96. PubMed ID: 17362921
[TBL] [Abstract][Full Text] [Related]
19. Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats.
Rahn EJ; Makriyannis A; Hohmann AG
Br J Pharmacol; 2007 Nov; 152(5):765-77. PubMed ID: 17572696
[TBL] [Abstract][Full Text] [Related]
20. Antinociceptive activity of chemical congeners of improgan: optimization of side chain length leads to the discovery of a new, potent, non-opioid analgesic.
Hough LB; de Esch IJ; Janssen E; Phillips J; Svokos K; Kern B; Trachler J; Abood ME; Leurs R; Nalwalk JW
Neuropharmacology; 2006 Sep; 51(3):447-56. PubMed ID: 16806300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]